Compounding HRT Solutions for Women Trying to Conceive

According to NIH MedlinePlus and ACOG, Mittelschmerz is mid-cycle pelvic pain that may present as mild to sharp, one-sided lower abdominal cramping occurring around the time of ovulation when the dominant follicle stretches and ruptures to release an egg. According to ACOG, the discomfort typically lasts minutes to a few hours but may persist up to 24 hours and may be accompanied by light spotting or increased cervical mucus. This symptom may serve as a physiological indicator of the ovulation window for women tracking fertility signs. Patients experiencing severe, persistent, or worsening pelvic pain should seek evaluation from a qualified clinician, as sudden severe pain may indicate a more serious condition requiring prompt medical attention.

According to NIH MedlinePlus and ACOG, increased cervical mucus is a normal physiological change that may occur in the days surrounding ovulation, reflecting rising estrogen levels during the follicular phase of the menstrual cycle. According to ACOG, cervical mucus may become more abundant, clear, and slippery in consistency — sometimes described as resembling raw egg whites — as ovulation approaches, and this change may support sperm motility and transport. Patients who notice sudden changes in discharge characteristics such as unusual color, odor, or associated irritation should seek evaluation from a qualified clinician, as these findings may indicate infection or other conditions requiring assessment.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, basal body temperature (BBT) rise is a subtle, sustained increase in resting body temperature that may follow ovulation as rising progesterone levels raise metabolic rate. According to these sources, the typical rise is approximately 0.3–0.6°C (0.5–1.0°F) and may remain elevated through the luteal phase; the rise generally appears the morning after ovulation and is confirmed by several consecutive higher readings. BBT charting is considered a retrospective indicator of a fertile cycle rather than a prospective predictor of ovulation. Patients who experience persistent temperature elevations outside of the expected luteal phase pattern, or who have concerns about cycle irregularity, should seek evaluation from a qualified clinician.

According to NIH MedlinePlus and ACOG, breast tenderness in women tracking fertility may present as a persistent aching fullness or sharp sensitivity in one or both breasts, which may reflect normal hormonal fluctuations across the menstrual cycle — particularly rising progesterone levels during the luteal phase. According to ACOG, the nipples may be particularly sensitive to touch, and discomfort from clothing or a bra may be noted; the sensation may be intermittent or constant and may vary in intensity, lasting from a few days to several weeks. Patients experiencing new, severe, or unilateral breast pain, or any breast changes such as lumps, nipple discharge, or skin changes, should seek evaluation from a qualified clinician, as these findings may indicate conditions requiring further assessment.

According to the FDA-approved prescribing information for Prometrium, Prometrium is a micronized progesterone capsule indicated for the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens and for the treatment of secondary amenorrhea. The labeling describes that progesterone transforms a proliferative endometrium into a secretory endometrium and that Prometrium is absorbed with food, resulting in higher peak serum concentrations compared to fasted administration. Per the labeling, adverse effects may include dizziness, abdominal cramping, bloating, headache, and breast tenderness; drowsiness may occur and patients should be cautioned about activities requiring mental alertness. According to the FDA-approved prescribing information for Prometrium and the Endocrine Society Clinical Practice Guideline, progesterone supplementation may be used in fertility-related clinical contexts such as luteal phase support, as determined by the prescribing clinician. Any compounded preparation involving progesterone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Prometrium products are separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for Estrace, Estrace (estradiol) is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause, vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration, or primary ovarian insufficiency, and for the treatment of advanced androgen-dependent carcinoma of the prostate and metastatic breast cancer. The labeling describes that estradiol binds to nuclear estrogen receptors and promotes growth and development of female reproductive tissue and related structures. Per the labeling, estrogens carry a boxed warning: increased risks of endometrial cancer, cardiovascular events, and breast cancer have been reported in clinical trials; estrogens should be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals, and patients should be evaluated regularly. According to the FDA-approved prescribing information for Estrace and the Endocrine Society Clinical Practice Guideline, estradiol may be used by prescribing clinicians in endometrial preparation protocols for frozen embryo transfer, as determined by clinical judgment. Any compounded preparation involving estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Estrace products are separately regulated, and clinical decisions belong with the prescribing clinician.